EZH2 and glioma: We validated the relationship between EZH2 expression and prognosis in both TCGA and CGGA databases, revealing that patients with high EZH2 expression (using the median expression level as the cut-off value) exhibit significantly worse prognosis compared to those with low EZH2 expression in both primary and recurrent gliomas (Fig. 1a and Fig. S1a, 1b).